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Abstract:
Background and Aims: Prostate cancer (PCa) is one of the most common cancer in the men.
The immune system plays an important role against tumor cells. The regulatory T (Treg) cell-
derived IL-35 is an immunosuppressive cytokine that may inhibits antitumor immune responses
and also IL-33 anovel identified cytokine with both pro- or anti-tumor activities, play important
roles in response against tumor cells. The aim of this study was to evaluate the serum levels of
IL-35 and IL-33 and single nucleotide polymoqphisms (SNP) in FOXP3 and IL-33 genes in
patients with PCa.
Material and Methods: In this case/control study, the blood samples collected from 150 PCa
patients (mean age 65.07 + 7.88, year) and 150 healthy men (mean age 64.00 t 8.91, years) as
a controi group.The serum levels of IL-35 and IL-33 and the mentioned SNPs were determined
by ELISA and PCR-restriction fragment length polymorphism (PCR-RFLP) methods,
respectively
Results: The mean serum IL-35 and IL-33 levels in patients with PCa were significantly higher
in comparison to healthy control group (P<0.0001 and P<0.0001, respectively). There were
significant differences between patients with Stages I, II, III and IV regarding the serum levels
of IL-33 and IL-35 (P<0.0001 and P<0.0001, respectively). In patients with prostate cancer, the
frequencies of AA genotype and A allele at rs3761548 were significantly higher than in healthy
controls (P <0.003, P <0.0001, respectively). Moreover, the frequencies of GG genotype and G
allele at rs1929992 were significantly higher than in healthy controls (P <0.003, P <0.014,
respectively). In both patients and control groups, the mean serum levels of IL-35 in subjects
with AA genotype or A allele at rs3761548 were also significantly higher as compared to
subjects with CC genotype or C allele (P <0.0001). On the other hand, in both patients and
control groups, the mean semm levels of IL-33 in subjects with GG genotype or G allele at
rs1929992 were also significantly higher as compared to subjects with AA genotype or A allele
(P <0.0001).
Conclusion: These findings represent that the IL-35 and lL-33 may contribute in tumor
development. The AA genotype and A allele at rs3761548 were more frequent in PCa patients.
Whereas, the GG genotype and G allele at rs1929992 were more frequent. The serum IL-35
md IL-33 levels were respectively affected by genetic variations at SNP rs3761548 and SNP
s1929992. Accordingly, these SNP may play arole in the susceptibility to PCa.
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